4. ASCOupdate 2011, Lymphoma und Myeloma

Diskussionsleiter Dr. L. Widmer, OnkoZentrum Hirslanden, Zürich, bespricht folgende Studien:

Abstract 8000: R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma

Abstract 8002: Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL)

Abstract 8010: Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results

Abstract 8009: Secondary Malignancies Following Multiple Myeloma

Abstract LBA4: Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma

Abstract LBA5: Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma

Leave a Reply

Your email address will not be published. Required fields are marked *